CM 383
Alternative Names: CM-383Latest Information Update: 04 Oct 2024
At a glance
- Originator KeyMed Biosciences
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 01 Oct 2024 Keymed Biosciences plans a phase I trial for Alzheimer Disease (In adults, In the elderly) (IV, Infusion), in December 2024 (NCT06619613)
- 30 Jun 2024 Phase-I clinical trials in Alzheimer's disease (In volunteers) in China (Parenteral) (NCT06412185)
- 26 Mar 2024 KeyMed Biosciences plans a phase I trial in healthy volunteers